TOBI Podhaler is for people 6 years and older with cystic fibrosis (CF), Pseudomonas aeruginosa (Pa), and forced expiratory volume in 1 second (FEV1) 25% to 80% predicted and who do not have Burkholderia cepacia.1

REASONS WHY TOBI PODHALER MAY BE RIGHT FOR YOU

For appropriate patients

WHY CHOOSE TOBI PODHALER?

  • IMPROVED LUNG FUNCTION

    IN A CLINICAL TRIAL VS PLACEBO

  • FEWER RESPIRATORY-RELATED HOSPITALIZATIONS

    IN A CLINICAL TRIAL VS PLACEBO

  • ADMINISTERED IN 2-7 MINUTES*

    PORTABLE | CLEANUP

    As observed in a clinical trial

  • ESTABLISHED SAFETY PROFILE

    Clinical trial program evaluated safety in 425 patients with CF.

  • PODCARE+®

    ENHANCED CO-PAY AND INSURANCE SUPPORT PROGRAM.

    LIMITATIONS APPLY.

podcare+

Podcare+ can help eligible patients with co-pay assistance, insurance, and specialty pharmacy support.

Learn more

REAL PATIENT STORIES

Meet real patients and learn how they manage with TOBI Podhaler

Watch videos

USING TOBI PODHALER

Watch a video on how to use TOBI Podhaler.

Watch video

TOBI Podhaler was evaluated for safety in 425 patients with CF exposed to at least 1 dose of TOBI Podhaler, including 273 patients who were exposed across 3 cycles. The most common side effects of TOBI Podhaler include cough, worsening of lung problems or cystic fibrosis, productive cough, shortness of breath, fever, sore throat, changes in voice (hoarseness), coughing up blood, headache, and altered taste.1

Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program, for cash-paying patients, where product is not covered by patient's commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the US and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. Novartis reserves the right to rescind, revoke or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. Patient pays a $0 co-pay for each use of TOBI Podhaler and Novartis pays up to $14,000 annually. This program is subject to termination or modification at any time.

Reference: 1. TOBI Podhaler [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.

IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is a prescription inhaled medication for cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa.

It is not known if TOBI Podhaler is safe and effective in patients under 6 years of age, in those with lung function outside of a certain range, or in those whose lungs contain bacteria called Burkholderia cepacia.

IMPORTANT SAFETY INFORMATION

You should not use TOBI Podhaler if you are allergic to it or to any other aminoglycoside antibacterial.

Tell your doctor before starting treatment if you have or have had hearing, kidney, breathing, or muscle weakness problems or if you have dizziness, an organ transplant, or are pregnant or nursing.

Tell your doctor about all the drugs you take. Ask if you should take other medicines that may harm your nervous system, kidneys, or hearing; "water pills" (diuretics) such as Edecrin (ethacrynic acid), Lasix (furosemide), or mannitol; or urea.

TOBI Podhaler can cause serious side effects, including hearing loss or ringing in the ears. Tell your doctor right away if you have hearing loss, noises in your ears such as ringing or hissing, vertigo, difficulty with balance, or dizziness.

TOBI Podhaler is in a class of drugs that may worsen kidney problems, especially in people with known or suspected kidney problems. Your health care provider may do a blood test to check how your kidneys are working while you are using TOBI Podhaler.

TOBI Podhaler is in a class of drugs that may worsen muscle weakness problems or harm an unborn baby.

TOBI Podhaler can cause severe breathing problems (bronchospasm). Tell your doctor right away if you get shortness of breath with wheezing, or coughing and chest tightness.

The most common side effects of TOBI Podhaler include cough, worsening of lung problems or cystic fibrosis, productive cough, shortness of breath, fever, sore throat, changes in your voice (hoarseness or loss of voice), coughing up blood, headache, and altered taste.

Let your doctor know if your symptoms worsen or if you have a side effect that bothers you enough to stop treatment or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.